Aralez Pharmaceuticals — Cowen Healthcare Conference 2016
16 slides from Aralez Pharmaceuticals's conference presentation, Mar 7, 2016

Slide 1: Forward-looking statements
This presentation includes certain statements that constitute “forward-looking statements” within the meaning of applicable securities laws in Canada and United States. Forward-looking statements include, but are not limited to, statements regarding statements about the expected benefits of the merg

Slide 2: Aralez: A Compelling Platform for Growth
Aralez: A Compelling Platform for Growth Strong Management with History of Success Diversified, Growing Revenue Base with North American Focus Strong Balance Sheet & Financial Position Canadian Domicile & Irish Presence Offers Financial & Competitive Advantage $150M at close* ($75M equity/$75M conve

Slide 3: The Aralez Investment Thesis
The Aralez Investment Thesis Aralez is a new global specialty pharmaceutical company designed to: Maximize the value of expanded portfolio, growing revenue base and geographic footprint across North America and Europe Build on our anchor positions in cardiovascular disease and pain management and op

Slide 4: Focus on Cardiovascular & Pain Therapies
Focus on Cardiovascular & Pain Therapies YOSPRALA™: Combination of delayed-release aspirin and immediate-release omeprazole for the secondary prevention of heart attack and stroke in patients at risk for developing aspirin-associated gastric ulcers NDA re-submission in 2Q 2016; targeted US launch in

Slide 5: Aralez: Regulatory Status
Aralez: Regulatory Status US: PA32540/PA8140 NDA filing (YOSPRALA) 505b(2) application Proposed label for secondary prevention of CVD per aspirin monograph (excluding acute MI) Plan to resubmit NDA early 2Q 2016 using our new primary aspirin supplier and an alternative supplier Anticipated 4Q 2016 a

Slide 6: Fibricor: Opportunity in Perspective
Fibricor: Opportunity in Perspective Fibricor is a fenofibric acid formulation that is a lipid regulating agent indicated as adjunctive therapy to diet for treatment of severe hypertriglyceridemia (> 500 mg/dL), primary hypercholesterolemia or mixed dyslipidemia Fibricor and its Authorized Generic v

Slide 7: YOSPRALA – Product Background
YOSPRALA – Product Background YOSPRALA™: Combination of delayed-release enteric-coated (EC) aspirin (325mg or 81mg core) and immediate-release omeprazole (40mg) for the secondary prevention of heart attack and stroke for patients at risk for an aspirin-induced ulcer Fixed-dose aspirin/PPI tablet des

Slide 8: YOSPRALA: US Market Opportunity
YOSPRALA: US Market Opportunity YOSPRALA has the ability to achieve mid single digit market share in the secondary prevention patient population Upon FDA approval, plan to launch YOSPRALA with ~110 sales professionals (including 25 previously hired for Fibricor), targeting top 29% of secondary preve

Slide 9: YOSPRALA: US Market Share Opportunity
YOSPRALA: US Market Share Opportunity Q1. (n=268) Thinking of your secondary prevention patients, approximately what percent receive each of the following antiplatelet medications for secondary prevention of cardiovascular events? Q3. (n=268) First, based on the information you were provided, how, i

Slide 10: YOSPRALA: Preparations
YOSPRALA: Preparations Confirmed launch pricing for YOSPRALA Received feedback from KOL, Professional, and Advocacy groups Developed comprehensive and logical commercial messaging platform Developed and tested compelling branded and unbranded platforms Received positive feedback regarding optimal pr

Slide 11: Tribute History: A Canadian Growth Story
Tribute History: A Canadian Growth Story Tribute, a Canadian specialty pharmaceutical company, founded in January 2006 as a private company Strong history of driving growth through value-creating acquisitions and partnerships Collatamp® G in May 2012 Bilastine in May 2014 Fiorinal®, Fiorinal® C, Vis

Slide 12: Aralez - Canadian Growth Drivers
Aralez - Canadian Growth Drivers Cambia® Exclusive license in Canada from Depomed, Inc. Cambia (diclofenac) was approved by Health Canada in 2009 for the acute treatment of migraine attached with or without aura in adults 18 years of age or older The only prescription NSAID available, approved for a

Slide 13: Business Development: Framework and Focus
Business Development: Framework and Focus EBITDA accretive* and near-term revenue generating products Approved products in Cardiovascular and Pain anchor areas Opportunistic approach to other specialty therapeutic areas meeting specified criteria US, Canada and ex-North American geographies Aligned,

Slide 14: Our Near Term Priorities
Our Near Term Priorities Complete Integration of Tribute Pharmaceuticals Canada Inc. Continued financially disciplined build up of organization Prepare for sales force deployment in April 2016 to promote Fibricor Advance YOSPRALA to re-submission in the 2Q 2016, prepare for anticipated launch in 4Q

Slide 15: Corporate Overview & Strategic Vision
“Corporate Overview & Strategic Vision” Cowen Healthcare Conference March 7, 2016

Slide 16: Aralez Pharmaceuticals – Cowen Healthcare Conference
/rale2 Pharmaceuticals Breathing New Life Into Pharmaceuticals™ Cowen Healthcare Conference “Corporate Overview & Strategic Vision” March 7, 2016
Source: SEC EDGAR · 8-K filed Mar 7, 2016


